Zomedica Announces Key Educational Presentations at Fetch dvm360 Veterinary Conference
Leading veterinary experts to present at the Fetch dvm360 Veterinary Conference in Kansas City, August 23-25, 2024
ANN ARBOR, MI / ACCESSWIRE / August 20, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced its sponsorship of educational programs at the upcoming Fetch dvm360 Veterinary Conference, taking place in Kansas City, MO, from August 23-25, 2024.
"We are proud to continue our partnership with the Fetch dvm360 series of veterinary Continuing Education programs," commented Nicole Westfall, Zomedica's Senior Vice President of Marketing. "The Kansas City conference provides an exceptional platform for education, featuring some of the most respected experts in veterinary medicine. We are honored to sponsor presentations by distinguished speakers who will share their invaluable knowledge and insights, furthering the advancement of veterinary practice and patient care."
Kevin Klass, Zomedica's Senior Vice President of Sales, added, "Our TRUFORMA® Bulk Acoustic Wave diagnostic platform, PulseVet® shock wave platform, and the VETGuardian® zero-touch remote monitor have made significant strides, expanding into global markets and introducing innovative applications. The Fetch dvm360 conference in Kansas City provides an excellent opportunity for us to showcase the capabilities of these systems. We look forward to connecting with professionals eager to enhance patient care and practice efficiency through our cutting-edge diagnostic and therapeutic solutions."
Zomedica will be exhibiting at Booth #409 during the Fetch Kansas City Conference.
The Company is sponsoring the following presentations by leading experts in veterinary medicine:
Heidi Lobprise, DVM, DAVDC presents "Step Up to Optimal Periodontal Therapy" on Friday, August 23rd from 11:00am - 12:00pm
Ashley Bourgeois, DVM, DACVD presents "Digital Derm: How to Implement Cytology in Your Busy Practice" on Saturday, August 24th from 9:15am - 10:15am
David Dycus, DVM, MS, CCRP, DACVS-SA presents "My Patient Has A Front Limb Lameness - Now What? Soft Tissue Orthopedic Injuries" on Saturday, August 24th from 1:30pm - 2:30pm
Courtney Campbell, DVM, DACVS-SA presents "Beyond Surgery: Conventional Untapped Remedies for Maximizing Postoperative Success" on Saturday, August 24th from 2:45pm - 3:45pm
Gary Oswald, DVM, MS, DACVIM (Int Med) presents "Have the 'Guts' to Run These Tests? Gastrointestinal Blood Panels" on Saturday, August 24th from 4:30pm - 5:30 pm
About Zomedica
Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW™ digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. An NYSE American company, Zomedica grew revenue 33% in 2023 to $25 million and maintains a strong balance sheet with approximately $83 million in liquidity as of June 30, 2024. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as we work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit www.zomedica.com.
Follow Zomedica
Email Alerts: http://investors.zomedica.com
Facebook: https://m.facebook.com/zomedica
X (formerly Twitter): https://twitter.com/zomedica
Instagram: https://www.instagram.com/zomedica_inc
Cautionary Note Regarding Forward-Looking Statements
Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition.
Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the expected market and Zomedica's share of such market, continued growth of sales, the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work including the development of new cartridges; uncertainty as to the timing and results of verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate acquisitions; uncertainty as to our ability to supply products in response to customer demand; and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products, particularly in the Middle East, Africa and India; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contact:
Zomedica Investor Relations
[email protected]
1-734-369-2555
SOURCE: Zomedica Corp.
View the original press release on accesswire.com